NASDAQ Global Market • Healthcare • Biotechnology • IL • USD
Silexion Therapeutics Ltd. (SLXN) has a consensus analyst rating of Buy, based on 1 analyst covering the stock. Of those, 1 recommend buying, 0 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
